Objective To assess the efficacy/safety of the B lymphocyte stimulator inhibitor belimumab
plus standard therapy compared with placebo plus standard therapy in active systemic lupus …

Objective To assess the efficacy and safety of subcutaneous (SC) belimumab in patients
with systemic lupus erythematosus (SLE). Methods Patients with moderate‐to‐severe SLE (…

Infiltrating leukocytes may be responsible for autoimmune disease. We hypothesized that
the chemokine monocyte chemoattractant protein (MCP)-1 recruits macrophages and T cells …

CSF-1 and TNF-α in the kidney of MRL-Fas lpr mice are proximal events that precede and
promote autoimmune lupus nephritis, while apoptosis of renal parenchymal cells is a feature …

Monocyte chemoattractant protein-1 (MCP-1) is upregulated in renal parenchymal cells during
kidney disease. To investigate whether MCP-1 promotes tubular and/or glomerular injury, …

Introduction Evidence from a number of open-label, uncontrolled studies has suggested that
rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-…

The B cell activating factor (BAFF), or B lymphocyte stimulator (BLyS), is a B cell survival
factor which supports autoreactive B cells and prevents their deletion. BAFF expression is …

Anti Jo-1 antibodies are the main markers of the antisynthetase syndrome (ASSD), an
autoimmune disease clinically characterized by the occurrence of arthritis, myositis, and interstitial …

Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the
occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung …

Objective. To investigate the pathophysiological effect of interleukin 6 (IL-6) on lupus nephritis
in MRL-Fas lpr mice. Methods. We generated IL-6-deficient MRL-Fas lpr mice using a …